Patents Represented by Attorney Valeta Gregg, Esq.
  • Patent number: 6274608
    Abstract: Disclosed are novel compounds of formula I wherein R1, R2, R3, L, X and Y are as defined in the specification. These compounds are useful in the treatment of conditions mediated by nuclear receptors, in particular the Retinoid X Receptor (RXR) and the Peroxisome Proliferator-Activated Receptor (PPAR) families. Such conditions include diabetes and obesity.
    Type: Grant
    Filed: April 18, 2000
    Date of Patent: August 14, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Per Sauerberg, Anthony Murray, Lone Jeppesen, Paul Stanley Bury, Ingrid Pettersson
  • Patent number: 6271229
    Abstract: The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 7, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Beverley Greenwood
  • Patent number: 6265419
    Abstract: The present invention relates to a novel method for treating a mammal suffering from gastrointestinal motility disorders.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: July 24, 2001
    Assignee: Novo Nordisk A/S
    Inventor: Beverley Greenwood
  • Patent number: 6251856
    Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the &agr;-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: June 26, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Jan Markussen, Ib Jonassen, Svend Havelund, Jakob Brandt, Peter Kurtzhals, Per Hertz Hansen, Niels Christian Kaarsholm
  • Patent number: 6248781
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
    Type: Grant
    Filed: October 19, 1999
    Date of Patent: June 19, 2001
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
  • Patent number: 6207009
    Abstract: A process for producing paper or paperboard from mechanical pulp, in which the pulp is treated with a phenol-oxidizing enzyme after mechanical refining of the pulp has been completed. The resulting paper exhibits an increased strength relative to paper produced from untreated pulp.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: March 27, 2001
    Assignee: Novo Nordisk Biochem North America, Inc.
    Inventors: Tomas Tage Hansen, Peder Holk Nielsen
  • Patent number: 6190883
    Abstract: The invention describes industrial fermentation of a Saccharomyces yeast species for production of a heterologous product encoded by a plasmid or DNA contained in said Saccharomyces yeast species which method utilizes the substrate more efficiently and without fermentative metabolism resulting in formation of ethanol and other unwanted primary products of fermentative activity whereby high yields of the heterologous product are obtained. The Saccharomyces yeast species is preferably a Crabtree negative Saccharomyces species in particular Saccharomyces kluyveri.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: February 20, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Aradhana Srivastava, Jure Piskur, Jens Nielsen, Michi Egel-Mitani
  • Patent number: 6183989
    Abstract: The invention describes a process for making desired polypeptides in yeast. The desired products are expressed as leader bound polypeptides connected by means of a monobasic processing site. The desired polypeptide is cleaved from the leader either in vivo or in vitro by enzymatic cleavage.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: February 6, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Jacob Brandt, Knud Vad
  • Patent number: 6087315
    Abstract: The present invention relates to protease variants, stabilized towards the inactivation caused by peroxidase systems, in which protease variants a naturally occurring tyrosine residue has been deleted or substituted with a different amino acid residue at one or more positions. The invention also relates to a method of stabilizing a protease towards the inactivation caused by peroxidase systems, and detergent compositions comprising a protease variant of the invention.
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: July 11, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Grethe Rasmussen, Egon Nielsen, Torben Halkier
  • Patent number: 6074863
    Abstract: A lipase variant of a parent lipase comprising a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule and, located in a critical position of a lipid contact zone of the lipase structure, an amino acid residue different from an aromatic amino acid residue, which amino acid residue interacts with a lipid substrate at or during hydrolysis, in which lipase variant said amino acid residue has been replaced by an aromatic amino acid residue so as to confer to the variant an increased specific activity as compared to that of the parent lipase. The parent lipase may be a C. antarctica lipase A essentially free from other substances from C. antarctica, which comprises the amino acid sequence shown in SEQ ID No. 2, or a variant of said lipase which (1) has lipase activity, (2) reacts with an antibody reactive with at least one epitope of C. antarctica lipase A having th eamino acid sequence SEQ ID No.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: June 13, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Allan Svendsen, Shamkant Anant Pathar, Michi Egel-Mitani, Kim Borch, Ib Groth Clausen, Mogens Trier Hansen
  • Patent number: 6066486
    Abstract: A cholesterol esterase from Pseudomonas fragi FERM BP-1051 can be used to hydrolyze cholesterol ester. The enzyme can be used in cleaning compositions.
    Type: Grant
    Filed: September 27, 1995
    Date of Patent: May 23, 2000
    Assignee: Novo Nordisk A/S
    Inventor: Martin Barfoed
  • Patent number: 6060091
    Abstract: A method of making an animal fodder stabilized against microbial degradation, by jet-cooking potato pulp at a temperature of between about 125.degree. C. and 140.degree. C. for between about 20 to 100 seconds, cooling the jet-cooked potato pulp, and adding a cell-wall degrading enzyme to the cooled potato pulp in order to enzymatically degrade the cell walls in the potato pulp, wherein a fodder stabilized against microbial degradation is produced.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: May 9, 2000
    Assignee: Novo Nordisk A/S
    Inventor: Hans Sejr Olsen
  • Patent number: 6051689
    Abstract: The present invention relates to a recombinant glucagonlike peptide-1 (GLP-1) receptor having the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, wherein the receptor polypeptide binds GLP-1 with a Kd of less than 100 nM.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: April 18, 2000
    Assignee: Novo Nordisk A/S
    Inventor: Bernard Thorens
  • Patent number: 6020180
    Abstract: A DNA sequence encoding a lipase having the amino acid sequence shown in SEQ ID NO:2. The lipase has a trypsin-like catalytic triad including an active serine located in a predominantly hydrophobic, elongated binding pocket of the lipase molecule and, located in a critical position of a lipid contact zone of the lipase structure, an amino acid residue different from an aromatic amino acid residue, which amino acid residue interacts with a lipid substrate at or during hydrolysis, in which lipase variant of the amino acid residue has been replaced by an aromatic amino acid residue so as to confer to the variant an increased specific activity as compared to that of the parent lipase.
    Type: Grant
    Filed: July 8, 1998
    Date of Patent: February 1, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Allan Svendsen, Shamkant Anant Patkar, Michi Egel-Mitani, Kim Borch, Ib Groth Clausen, Mogens Trier Hansen
  • Patent number: 6017749
    Abstract: This invention relates to Alkalophilic Bacillus sp. AC13 microorganisms and cultures, and mutants and variants thereof, and to enzymes obtainable from the microorganism.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: January 25, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Claus Dambmann, Arne Agerlin Olsen, Henrik Bisg.ang.rd-Frantzen, Martin Schulein
  • Patent number: 6001134
    Abstract: Oxidation dyeing compositions for keratinous fibers which contain an oxidation enzyme derived from a strain of the genus Pyricularia, one or more dye precursors, and optionally, one or more modifiers, and methods for dyeing hair with such compositions.
    Type: Grant
    Filed: September 22, 1998
    Date of Patent: December 14, 1999
    Assignee: Novo Nordisk A/S
    Inventor: Niels Henrik S.o slashed.rensen
  • Patent number: 6001639
    Abstract: The present invention relates to enzyme preparations consisting essentially of an enzyme which has cellulytic activity and comprises a first amino acid sequence consisting of 14 amino acid residues having the following sequenceThr Arg Xaa Xaa Asp Cys Cys Xaa Xaa (SEQ ID NO:79) 1 2 3 4 5 6 7 8 9 - Xaa Cys Xaa Trp Xaa 10 11 12 13 14and a second amino acid sequence consisting of 5 amino acid residues having the following sequenceTrp Cys Cys Xaa Cys (SEQ ID NO:80) 1 2 3 4 5wherein, in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe; in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe; in position 8 of the first sequence, the amino acid is Arg, Lys or His; in position 9, 10, 12 and 14, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino acid residues with the provisos that, in the first amino acid sequence, (i) when the amino residue in position 12 is Ser, then the amino acid residue in posit
    Type: Grant
    Filed: May 21, 1996
    Date of Patent: December 14, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Martin Schulein, Lene Nonboe Andersen, S.o slashed.ren Flensted Lassen, Markus Sakari Kauppinen, Lene Lange, Ruby Iium Nielsen, Michiko Ihara, Shinobu Takagi
  • Patent number: 5994113
    Abstract: The present invention relates to a enzyme exhibiting aminopeptidase activity, a method for producting said enzyme, and enzyme preparation containing said enzyme exhibithing aminopeptidase activity, and use of said enzyme for various industrial purposes.
    Type: Grant
    Filed: September 15, 1997
    Date of Patent: November 30, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Markus Sakari Kauppinen, Joan Qi Si, Tina Spendler, Claus Dambmann, Torben Halkier, Peter Rahbek stergaard, Shamkant Anant Patkar, Kim Hansen
  • Patent number: 5981253
    Abstract: The present invention relates to novel microorganisms, novel enzymes obtainable herefrom, and to a method of producing the novel enzymes. More specifically, the invention relates to novel enzymes obtainable from strains of the novel alkalophilic species Bacillus sp. AC13. Moreover, the invention relates to a method for producing the enzymes of the invention, and to the use of the enzymes in detergents or in the paper pulp industry.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 9, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Helle Outtrup, Claus Dambmann, Arne Agerlin Olsen, Henrik Bisg.ang.rd-Frantzen, Martin Schulein
  • Patent number: RE37302
    Abstract: The invention employs GLP-1(7-37), GLP-1(7-36)amide, and certain related compounds in combination with an oral hypoglycaemic agent for treating diabetes mellitus.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: July 31, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Suad Efendic, Mark Gutniak, Ole Kirk